FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma
Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
Category: Oncology
CellCentric Secures $120 Million Investment to Develop Oral Myeloma Drug Inobrodib
CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.
Roche’s VENTANA MET (SP44) RxDx Assay Receives FDA Approval as First Companion Diagnostic for MET-Positive NSCLC
The VENTANA MET (SP44) RxDx Assay detects the MET, or c-Met, protein, which is overexpressed in about 25% of advanced NSQ-NSCLC patients with EGFR wild-type.
AbbVie’s EMRELISâ„¢ (telisotuzumab vedotin-tllv) Receives U.S. FDA’s Accelerated Approval for Adults With Small Cell Lung Cancer (NSCLC)
EMRELISâ„¢ (telisotuzumab vedotin-tllv) used for previously treated adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression.
Johnson & Johnson Launches MENTORâ„¢ MemoryGelâ„¢ Breast Implants for Reconstruction Patients
The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
Recent Cancer Research Shows Treatment Efficacy With Lupus-Related Antibody
Immunotherapies and other cancer treatments don’t work well on “cold” tumors, also known as immunological deserts, because they usually have few T cells.
Pfizer With Arvinas Announced Positive Results of Phase 3 VERITAC-2 Clinical Trial for Advanced or Metastatic Breast Cancer
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
A Rare Side Effect for Cancer Immunotherapy Detected
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The Risk of Inherited Cancer Can Be Caused by Changes in DNA and Other Biological Pathways
According to the researchers, these recurring patterns suggest potential therapeutic targets meant to prevent or slow the progression of cancer.
Patients With Kidney Cancer in Stages III and IV May Benefit from the Cancer Vaccination
Surgery to remove the tumor is the standard of care for individuals with stage III or IV clear cell renal cell carcinoma.
